Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Nkarta, Inc. (NKTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.57-9.25%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for NKTX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Fund operating plan into 2029 | Management aims to fund operations into 2029. | Intact | cash runway falls short of funding operations into 2029 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage biotech, not an established earnings compounder. The multi-year thesis is in a watch state, with low confidence and elevated risk.
The evidence snapshot provides no valuation or market-expectations data, so whether NKTX is cheap or expensive versus peers is unclear. There is also no direct evidence on what investors already assume about its clinical program or cash runway.
Near term, results are under pressure: NKTX reported two recent earnings misses, and its losses and expenses increased from the first to the second quarter of 2026. Management continues to advance NKX019 trials, including outpatient dosing, and says cash can fund operations into 2029, but ongoing cash burn and an elevated risk of another miss remain concerns.
Over the next few quarters, the thesis hinges on NKX019 trial enrollment and outpatient dosing progress, while management controls spending and preserves the stated cash runway. A guidance cut or weaker economic data would add risk; continued strength among healthcare bellwethers could support the sector backdrop.
For a 1 to 3 year view, NKTX is a low-confidence clinical development story with meaningful execution and funding risks, alongside a sector tailwind and continued trial activity. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Nkarta, Inc.'s published investment case. The stated target is Operating losses do not increase beyond $30.9M per quarter. |
| Under Pressure |
| operating losses increase beyond $30.9M per quarter |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Progress toward generating revenue | A supporting condition in Nkarta, Inc.'s published investment case. The stated target is Achieve first revenue generation by FY29. | Intact | no revenue generation by FY29 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.39 → $-1.52 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.39 | $6,500,000 | 3 / 6 |
| 2026-07-25 | $-1.39 | $6,500,000 | 3 / 6 |
| 2026-07-26 | $-1.39 | $6,500,000 | 3 / 6 |
| 2026-07-27 | $-1.39 | $6,500,000 | 3 / 6 |
| 2026-07-28 | $-1.65 | $0 | 3 / 6 |
| 2026-07-29 | $-1.65 | $0 | 3 / 6 |
| 2026-07-30 | $-1.65 | $0 | 3 / 6 |
| 2026-07-31 | $-1.65 | $0 | 3 / 6 |
| 2026-08-01 | $-1.39 | $6,500,000 | 3 / 6 |
| 2026-08-02 | $-1.65 | $0 | 3 / 6 |
| 2026-08-03 | $-1.65 | $0 | 3 / 6 |
| 2026-08-04 | $-1.39 | $6,500,000 | 3 / 6 |
| 2026-08-05 | $-1.39 | $6,500,000 | 3 / 6 |
| 2026-08-06 | $-1.39 | $6,500,000 | 3 / 6 |
| 2026-08-07 | $-1.39 | $6,500,000 | 3 / 6 |
| 2026-08-08 | $-1.65 | $0 | 3 / 6 |
| 2026-08-09 | $-1.65 | $0 | 3 / 6 |
| 2026-08-10 | $-1.39 | $6,500,000 | 3 / 6 |
| 2026-08-12 | $-1.39 | $6,500,000 | 3 / 6 |
| 2026-08-13 | $-1.77 | $0 | 3 / 5 |
| 2026-08-14 | $-1.39 | $6,500,000 | 3 / 6 |
| 2026-08-15 | $-1.39 | $6,500,000 | 3 / 6 |
| 2026-08-16 | $-1.39 | $6,500,000 | 3 / 6 |
| 2026-08-17 | $-1.39 | $6,500,000 | 3 / 6 |
| 2026-08-18 | $-1.39 | $6,500,000 | 3 / 6 |
| 2026-08-19 | $-1.39 | $6,500,000 | 3 / 6 |
| 2026-08-20 | $-1.49 | $6,500,000 | 3 / 6 |
| 2026-08-21 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-08-22 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-08-23 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-08-24 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-08-25 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-08-26 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-08-27 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-08-28 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-08-29 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-08-30 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-08-31 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-01 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-02 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-03 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-04 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-05 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-06 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-07 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-08 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-09 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-10 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-11 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-12 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-13 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-14 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-15 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-16 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-17 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-18 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-19 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-20 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-21 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-22 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-23 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-24 | $-1.49 | $6,500,000 | 4 / 6 |
| 2026-09-25 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-09-26 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-09-27 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-09-28 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-09-29 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-09-30 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-01 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-02 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-03 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-04 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-05 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-06 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-07 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-08 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-09 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-10 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-11 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-12 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-13 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-14 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-15 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-16 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-17 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-18 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-19 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-20 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-21 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-22 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-23 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-24 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-25 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-26 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-27 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-28 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-29 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-30 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-10-31 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-11-01 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-11-02 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-11-03 | $-1.52 | $6,500,000 | 4 / 6 |
| 2026-11-04 | $-1.52 | $6,500,000 | 3 / 6 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.